Trial Profile
A phase I/II trial of HER2.taNK in breast cancer
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 15 Feb 2022
Price :
$35
*
At a glance
- Drugs HER2 taNK (Primary)
- Indications Breast cancer
- Focus Adverse reactions; Therapeutic Use
- 26 Apr 2016 New trial record
- 15 Apr 2016 According to a NantKwest media release, this trial will be part of the Cancer Moonshot 2020 initiative and is planning to be initiated in the second half of 2016.